Manrique Iriarte
Internal Medicine · Naples, FLNPI 1003096587
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,169, 3.2 times the $361 reported in 2019.
Across 66 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tepha Inc$304
- Amgen$259
- Lilly USA, LLC$183
- Boehringer Ingelheim$177
- Pfizer$140
- Novartis$86
- plus $513 from 14 others
What the payments were for
- Food & beverage$1,661100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tepha Inc | 2 | $304 |
| Amgen | 14 | $259 |
| Lilly USA, LLC | 7 | $183 |
| Boehringer Ingelheim | 7 | $177 |
| Pfizer | 7 | $140 |
| Novartis | 4 | $86 |
| Novo Nordisk | 3 | $65 |
| Esperion Therapeutics, Inc. | 3 | $60 |
| Radius Health, Inc. | 2 | $52 |
| AstraZeneca | 3 | $46 |
| Inspire Medical Systems, Inc. | 1 | $44 |
| Johnson & Johnson | 2 | $41 |
| Exact Sciences | 2 | $39 |
| Corcept Therapeutics | 2 | $35 |
| Eisai Inc. | 1 | $28 |
| Medtronic | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Merck | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,661 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 184 | $98,992 |
| TradjentaLinagliptin | 195 | $98,399 |
| EliquisApixaban | 135 | $74,344 |
| OzempicSemaglutide | 70 | $66,467 |
| FarxigaDapagliflozin Propanediol | 72 | $39,676 |
| JardianceEmpagliflozin | 43 | $24,953 |
| EntrestoSacubitril/Valsartan | 41 | $21,366 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,127 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 91 | $10,990 |
| Spiriva RespimatTiotropium Bromide | 19 | $9,599 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,363 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $7,224 |
| Triazolam | 150 | $6,918 |
| Insulin Aspart FlexpenInsulin Aspart | 46 | $6,860 |
| Atorvastatin Calcium | 841 | $6,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat | $177 | $132,951257 claims |
| Johnson & JohnsonXarelto | $41 | $98,992184 claims |
| PfizerEliquis | $140 | $74,344135 claims |
| Novo NordiskOzempic | $65 | $66,46770 claims |
| AstraZenecaFarxiga | $46 | $39,67672 claims |
| NovartisEntresto | $86 | $21,36641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Naples
- Eric SalataNaples$71K
- Alejandro Blanco-FrancoNaples$64K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.